How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study

被引:50
作者
Birrell, FN [1 ]
Hassell, AB [1 ]
Jones, PW [1 ]
Dawes, PT [1 ]
机构
[1] Univ Manchester, ARC Epidemiol Unit, Manchester M13 9PT, Lancs, England
关键词
BCR core set; rheumatoid arthritis; SF-36;
D O I
10.1007/s100670050155
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the study was to show that the SF-36 is a practical tool for use on outpatients with RA, to examine the relationship between the SF-36 and indices of outcome in RA, and to compare the results with population norms and other disease states. Eighty-six consecutive RA patients attending the Haywood Hospital in Stoke-on-Trent and starting or changing second-line therapy were enrolled. Disease outcome was assessed using the American College of Rheumatology core set and all subjects completed the SF-36 health questionnaire. The cohort had moderately active disease (median ESR 46) and appreciable disability (median HAQ 1.875). Impairment of health status was moderate to marked by the SF-36, with significant differences from population norms and chronic disease states such as low back pain. Good correlations were observed between HAQ and physical function (r > 0.75, p < 10(-6)) and HAQ and social function (r > 0.61, p < 10(-6)). In contrast, SF-36 scales for physical and emotional role showed no association with activity measures. We concluded that, SF-36 is a practical tool for use in patients with RA. HAQ is associated with its physical and social function scales. Other SF-36 scales, such as physical and emotional role, are not associated with activity core set measures; this suggests different information is involved. RA has a considerable impact on health status compared to other diseases.
引用
收藏
页码:195 / 199
页数:5
相关论文
共 16 条
  • [1] [Anonymous], MED CARE
  • [2] Evaluating changes in health status: Reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders
    Beaton, DE
    HoggJohnson, S
    Bombardier, C
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (01) : 79 - 93
  • [3] Birrell FN, 1998, J RHEUMATOL, V25, P1709
  • [4] THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY CORE SET OF DISEASE-ACTIVITY MEASURES FOR RHEUMATOID-ARTHRITIS CLINICAL-TRIALS
    FELSON, DT
    ANDERSON, JJ
    BOERS, M
    BOMBARDIER, C
    CHERNOFF, M
    FRIED, B
    FURST, D
    GOLDSMITH, C
    KIESZAK, S
    LIGHTFOOT, R
    PAULUS, H
    TUGWELL, P
    WEINBLATT, M
    WIDMARK, R
    WILLIAMS, HJ
    WOLFE, F
    [J]. ARTHRITIS AND RHEUMATISM, 1993, 36 (06): : 729 - 740
  • [5] THE COMPARATIVE EFFICACY AND TOXICITY OF 2ND-LINE DRUGS IN RHEUMATOID-ARTHRITIS - RESULTS OF 2 METAANALYSES
    FELSON, DT
    ANDERSON, JJ
    MEENAN, RF
    [J]. ARTHRITIS AND RHEUMATISM, 1990, 33 (10): : 1449 - 1461
  • [6] MEASUREMENT OF PATIENT OUTCOME IN ARTHRITIS
    FRIES, JF
    SPITZ, P
    KRAINES, RG
    HOLMAN, HR
    [J]. ARTHRITIS AND RHEUMATISM, 1980, 23 (02): : 137 - 145
  • [7] THE SF-36 HEALTH SURVEY QUESTIONNAIRE - AN OUTCOME MEASURE SUITABLE FOR ROUTINE USE WITHIN THE NHS
    GARRATT, AM
    RUTA, DA
    ABDALLA, MI
    BUCKINGHAM, JK
    RUSSELL, IT
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1993, 306 (6890): : 1440 - 1444
  • [8] KIRWAN JR, 1986, BRIT J RHEUMATOL, V25, P206
  • [9] Performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. II. A comparison of the SF-36 with disease-specific measures
    Kvien, TK
    Kaasa, S
    Smedstad, LM
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) : 1077 - 1086
  • [10] MCCALLUM J, 1995, AUST J PUBLIC HEALTH, V19, P160